Efficacy and Safety of a Neurokinin-1 Receptor Antagonist in Postmenopausal Women With Overactive Bladder With Urge Urinary Incontinence
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: Urge urinary incontinence is the involuntary leakage of urine commonly occurring in older adults, particularly women. Preclinical evidence suggests that urge urinary incontinence may occur due to up-regulation of tachykinin mediated bladder/spinal reflex signaling. This study tested the hypothesis that aprepitant, a neurokinin-1 receptor antagonist, may be efficacious in the treatment of urge urinary incontinence. MATERIALS AND METHODS: This was a double-blind, randomized, placebo controlled, parallel group pilot study in which postmenopausal women with a history of urge urinary incontinence or mixed incontinence (with predominantly urge urinary incontinence) were assigned to receive a 160 mg capsule of aprepitant (61) or placebo (64) once daily for 8 weeks. The primary end point was percent change from baseline in average daily micturitions assessed by a voiding diary. Secondary end points included average daily total urinary incontinence and urge urinary incontinence episodes, and urgency episodes. RESULTS: Aprepitant significantly decreased the average daily number of micturitions compared with placebo at 8 weeks. The between-group treatment difference expressed as percent change from baseline was -6.8%, 95% CI (-12.5, -1.1) (p = 0.019). The average daily number of urgency episodes was also significantly reduced compared to placebo (p = 0.049). The average daily number of urge urinary incontinence and total urinary incontinence episodes were also reduced, although the difference was not statistically significant. Aprepitant was generally well tolerated and adverse experiences were generally mild. CONCLUSIONS: Results of this initial study suggest that neurokinin-1 receptor antagonism may represent a novel therapeutic approach to treating overactive bladder syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Cited by
Biological and Pharmacological Aspects of the NK1-Receptor
Garcia-Recio, S., & Gascón, P. (2015) · BioMed Research International · doi:10.1155/2015/495704 · Cited by 226
Ständer, S., & Luger, T. A. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-44605-8_14 · Cited by 67
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1638910 · Cited by 26
Metadata
- Authors
- Green, S. A., Alon, A., Ianus, J., McNaughton, K. S., Tozzi, C. A., & Reiss, T. F.
- Venue
- Journal of Urology
- Published
- 2006-12
- Volume
- 176
- Issue
- 6
- Pages
- 2535-2540
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2103495340
- Cited by
- 92
- References
- 1
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of a Neurokinin-1 Receptor Antagonist in Postmenopausal Women With Overactive Bladder With Urge Urinary Incontinence. https://app.cochat.ai/papers/10.1016/j.juro.2006.08.018
- The paper
- Green, S. A., Alon, A., Ianus, J., McNaughton, K. S., Tozzi, C. A., & Reiss, T. F. (2006). Efficacy and Safety of a Neurokinin-1 Receptor Antagonist in Postmenopausal Women With Overactive Bladder With Urge Urinary Incontinence. Journal of Urology. https://doi.org/10.1016/j.juro.2006.08.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.